Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. The company's discovery services offer the tools and testing methods for companies and researchers to identify and develop new compounds and molecular-based biomarkers for diagnostics and treatment of disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests; and has collaboration with Cellaria to develop precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone201-528-9200
Debt
Current Ratio0.46
Quick Ratio0.46
Price-To-Earnings
Sales & Book Value
Annual Sales$29.12 million
Price / Sales0.25
Price / Cash FlowN/A
Price / Book0.27
Profitability
Net Income$-20,880,000.00
Net Margins-87.08%
Return on Assets-49.36%
Miscellaneous
Employees245
OptionableOptionable
Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions
What is Cancer Genetics' stock symbol?
Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."
How were Cancer Genetics' earnings last quarter?
Cancer Genetics Inc (NASDAQ:CGIX) released its quarterly earnings results on Monday, November, 19th. The medical research company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.07. The medical research company had revenue of $5.94 million for the quarter, compared to analyst estimates of $8.09 million. Cancer Genetics had a negative return on equity of 121.10% and a negative net margin of 87.08%. View Cancer Genetics' Earnings History.
When is Cancer Genetics' next earnings date?
What price target have analysts set for CGIX?
3 equities research analysts have issued 12-month target prices for Cancer Genetics' stock. Their predictions range from $3.00 to $6.00. On average, they expect Cancer Genetics' share price to reach $4.50 in the next twelve months. This suggests a possible upside of 1,630.8% from the stock's current price. View Analyst Price Targets for Cancer Genetics.
What is the consensus analysts' recommendation for Cancer Genetics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cancer Genetics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cancer Genetics.
What are Wall Street analysts saying about Cancer Genetics stock?
Here are some recent quotes from research analysts about Cancer Genetics stock:
- 1. Maxim Group analysts commented, "Cancer Genetics (CGI) reported 3Q18 with revenues of $5.9M, down 16% sequentially from $7.0M in 2Q18. The company also saw a reduced gross margin of 22% compared to 31% in the prior quarter. Operating Expenses were ~$9.3M, this includes $2.3M in costs from the ongoing restructuring plan and the NovellusDx merger. These factors led to a net loss of ($8.5M). The company reported a cash balance of $1.2M. Our focus on CGI remains implementing the restructuring program to try to position the company to return to growth across the clinical, biopharma and discovery services. We also remain concerned regarding capital needs, which CGI is working to address. The NovellusDx merger, which is on track to close in early 2019, is expected to bring in an additional $10M through an equity investment. More details are below; maintain Hold." (11/20/2018)
- 2. According to Zacks Investment Research, "Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. " (7/3/2018)
Has Cancer Genetics been receiving favorable news coverage?
News articles about CGIX stock have trended somewhat negative on Wednesday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cancer Genetics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days.
Who are some of Cancer Genetics' key competitors?
Who are Cancer Genetics' key executives?
Cancer Genetics' management team includes the folowing people:
- Mr. John A. Roberts MBA, Pres, CEO, COO & Director (Age 59)
- Mr. Michael Glenn Miles, Chief Financial Officer
- Mr. Michael Brian McCartney, Chief Commercial Officer
- Dr. Ralf Brandt, Pres of Discovery & Early Devel. Services (Age 55)
- Dr. Weiyi Chen Ph.D., HCLD, Director of Molecular Diagnostics
How do I buy shares of Cancer Genetics?
Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cancer Genetics' stock price today?
One share of CGIX stock can currently be purchased for approximately $0.26.
How big of a company is Cancer Genetics?
Cancer Genetics has a market capitalization of $6.93 million and generates $29.12 million in revenue each year. The medical research company earns $-20,880,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cancer Genetics employs 245 workers across the globe.
What is Cancer Genetics' official website?
How can I contact Cancer Genetics?
Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]
MarketBeat Community Rating for Cancer Genetics (NASDAQ CGIX)
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe CGIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
